Understanding the Long-term Impact of COVID on Children and Families

Sponsor
NYU Langone Health (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05172011
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (NIH)
40,000
Enrollment
72
Locations
39.2
Anticipated Duration (Months)
555.6
Patients Per Site
14.2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals age 0-25 years who will enter the cohort with and without SARS-CoV-2 infection at varying stages before and after infection. Individuals with and without SARS-CoV-2 infection and with or without PASC symptoms will be followed to identify risk factors and occurrence of PASC. This study will be conducted in the United States and participants will be recruited through inpatient, outpatient, and community-based settings. Study data including age, demographics, social determinants of health, medical history, vaccination history, details of acute SARS-CoV-2 infection, overall health and physical function, and PASC symptoms will be reported by participants or collected from the electronic health record using a case report form at specified intervals. Biologic specimens will be collected at specified intervals, with some tests performed in local clinical laboratories and others performed by centralized research centers or banked in the Biospecimen Repository. Advanced clinical examinations and radiologic examinations will be performed at local study sites with cross-site standardization.

Condition or DiseaseIntervention/TreatmentPhase

    Detailed Description

    Ambidirectional longitudinal meta-cohort study (combined retrospective and prospective) with nested case-control studies.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    40000 participants
    Observational Model:
    Other
    Time Perspective:
    Other
    Official Title:
    NIH RECOVER: A Multi-site Observational Study of Post-acute Sequalae of SARS-CoV-2 Infection in Children
    Anticipated Study Start Date :
    Feb 14, 2022
    Anticipated Primary Completion Date :
    Apr 1, 2025
    Anticipated Study Completion Date :
    May 23, 2025

    Arms and Interventions

    ArmIntervention/Treatment
    Extant, Clinical and De Novo Cohort -- INFECTED

    SARS-CoV-2 infected children and young adults with and without current or prior PASC-like symptoms, including infected individuals with history of multisystem inflammatory syndrome in children (MIS-C), and infants born in the context of maternal SARS-CoV-2 infection during pregnancy

    Extant, Clinical and De Novo Cohort -- UNINFECTED

    SARS-CoV-2 uninfected children and infants born to uninfected mothers

    Acute Cohort -- INFECTED

    Newly SARS-CoV-2 infected individuals (≤4 weeks since onset of symptoms or positive laboratory testing)

    Acute Cohort -- UNINFECTED

    Contemporaneous SARS-CoV-2 uninfected individuals selected from the same population as newly SARS-CoV-2 infected individuals

    Post-acute cohort -- INFECTED

    Post-acute infected individuals (>4 weeks after initial symptoms or positive laboratory testing) in the extant, clinical and de novo cohorts, including infants born in the context of maternal SARS-CoV-2 infection during pregnancy, will be enrolled 1-24 months after initial SARS-CoV-2 infection.

    Post-acute cohort -- UNINFECTED

    Uninfected individuals will be derived from a similar population with respect to age, sex, race and ethnicity, geographic origin, sociodemographics, and time of enrollment as the infected individuals.

    Post-COVID Vaccine Myocarditis

    Individuals with history of myocarditis after receiving COVID-19 vaccine.

    Primary Caregivers

    The primary caregiver of the child or young adult may optionally participate in the study.

    Biological Parent

    If the primary caregiver is a biological parent, the other biological parent may optionally participate in the study

    Outcome Measures

    Primary Outcome Measures

    1. Caregiver SARS-CoV-2 Infection Status [Baseline]

      Initial SARS-CoV-2 infection is reported via remote patient report (electronic, paper or telephone assessments) and EHR. Infection categories include: SARS CoV 2 PCR result, SARS CoV 2 antigen result, SARS CoV 2 antibody result, SARS CoV 2 sequencing performed, diagnosed by a doctor based on symptoms, suspected by participant but not diagnosed by a doctor.

    2. Child SARS-CoV-2 Infection Status [Baseline]

      Initial SARS-CoV-2 infection is reported via remote patient report (electronic, paper or telephone assessments) and EHR. Infection categories include: SARS CoV 2 PCR result, SARS CoV 2 antigen result, SARS CoV 2 antibody result, SARS CoV 2 sequencing performed, diagnosed by a doctor based on symptoms, suspected by participant but not diagnosed by a doctor.

    3. Caregiver Severity of SARS-CoV-2 Infection [Baseline]

      Severity levels are reported via remote patient report (electronic, paper or telephone assessments) and EHR. NIH severity levels include: asymptomatic or presymptomatic, mild illness, moderate illness, severe illness, and critical illness.

    4. Child Severity of SARS-CoV-2 Infection [Baseline]

      Severity levels are reported via remote patient report (electronic, paper or telephone assessments) and EHR. NIH severity levels include: asymptomatic or presymptomatic, mild illness, moderate illness, severe illness, and critical illness.

    5. Caregiver Previous In-Hospital SARS-CoV-2 Treatment Record [Baseline]

      Treatments will be reported via remote patient report (electronic, paper, or telephone assessment) and EHR -- Treated with corticosteroids , Treated with hydroxychloroquine, Treated with lopinavir, ritonavir, other antiviral, Treated with monoclonal antibody, Treated with therapeutic anticoagulation, Treated with antibiotics.

    6. Child Previous In-Hospital SARS-CoV-2 Treatment Record [Baseline]

      Treatments will be reported via remote patient report (electronic, paper, or telephone assessment) and EHR -- Treated with corticosteroids , Treated with hydroxychloroquine, Treated with lopinavir, ritonavir, other antiviral, Treated with monoclonal antibody, Treated with therapeutic anticoagulation, Treated with antibiotics.

    7. Caregiver Symptoms [Baseline, up to Month 48]

      Symptoms will be reported via remote patient report, in-person patient report, or EHR

    8. Child Symptoms [Baseline, up to Month 48]

      Symptoms will be reported via remote patient report, in-person patient report, or EHR -- symptoms include: Nasal Congestion, Trouble breathing, Pain when breathing, Chest pain, Palpitations/heart racing, Dizziness/lightheadedness, Fainting, Change in hearing/ringing in ears, Blurred vision, Change in smell, Change in taste, Problems with teeth or gums, Tremors/shakiness, Feeling off-balance or unsteady, Feeling tingling or "pins and needles", Seizures/fits, Muscle weakness, Difficulty sleeping, Excessive sleepiness, Fatigue/Low energy, Feeling exhausted after walking, Poor appetite, Stomach pains/cramps, Nausea, Vomiting, Diarrhea, Constipation, Problems with urination, Skin rash, Problems with memory, Problems with concentration, Speech difficulty, Anxiety, Depression, Body pain, Headache, Problems swallowing or chewing, Change in menstruation

    9. Caregiver SARS-CoV-2 Vaccination Status [Baseline, up to Month 48]

      Vaccination in status will be reported via remote patient report, in-person patient report, or EHR.

    10. Change in Child SARS-CoV-2 Vaccination Status [Week 8, up to Month 48]

      Vaccination in status will be reported via remote patient report, in-person patient report, or EHR.

    11. Change in Caregiver SARS-CoV-2 Treatment Record [Month 12, up to Month 48]

      Treatments will be reported via remote patient report, in-person patient report, or EHR -- Treated with corticosteroids, Treated with hydroxychloroquine, Treated with lopinavir, ritonavir, other antiviral, Treated with monoclonal antibody, Treated with therapeutic anticoagulation, Treated with antibiotics.

    12. Change in Child SARS-CoV-2 Treatment Record [Week 8, up to Month 48]

      Treatments will be reported via remote patient report, in-person patient report, or EHR -- Treated with corticosteroids, Treated with hydroxychloroquine, Treated with lopinavir, ritonavir, other antiviral, Treated with monoclonal antibody, Treated with therapeutic anticoagulation, Treated with antibiotics.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A to 25 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    Infected Cohort:
    Patients will be eligible for inclusion according to the following criteria:
    1. Ages newborn-25 years

    2. Infected individuals will have suspected, probable, or confirmed SARS-CoV-2 infection as defined by WHO criteria within 24 months of enrollment or have been born to a mother meeting these criteria during pregnancy (congenitally exposed)

    3. Children/young adults with or without history of MIS-C are eligible

    4. Children/young adults with or without history of SARS-CoV-2 vaccination are eligible

    5. Children/young adults with evidence of past SARS-CoV-2 infection based on serum antibody profile are eligible (with or without history of acute symptoms)

    6. Children/young adults with recurrent SARS-CoV-2 infections and those with post-vaccination (breakthrough) infections are eligible to participate

    7. Participants are eligible without exclusion related to sex, race/ethnicity, geography, nationality, severity of disease, or underlying health conditions

    Children/Young Adults with Suspected SARS-Cov-2 Infection

    Children/young adults who meet these clinical criteria:
    At least one of these clinical criteria:
    • Acute onset of fever and cough OR

    • Acute onset of ANY THREE OR MORE of the following signs or symptoms: fever, cough, general weakness /fatigue, headache, myalgia, sore throat, coryza, dyspnea, anorexia/nausea/vomiting, diarrhea, altered mental status.

    AND at least one of these epidemiological criteria:
    1. Residing or working in an area with a high risk of transmission of virus: closed residential, school or camp settings anytime within the 14 days before symptom onset; OR

    2. Residing or travel to an area with community transmission anytime within the 14 days before symptom onset; OR

    3. Any known household contact or any member of the household working in any health care setting, including within health facilities or within the community; anytime within the 14 days before symptom onset.

    4. A patient with history of severe acute respiratory illness (SARI):

    • SARI: acute respiratory infection with history of fever or measured fever of ≥ 38 C°; and cough; with onset within the last 10 days; and requires hospitalization
    1. An asymptomatic person not meeting epidemiologic criteria with a positive SARS-CoV-2 Antigen-RDT.

    Children/Young Adults with Probable SARS-Cov-2 Infection

    1. A patient who meets clinical criteria above AND is a contact of a probable or confirmed case or linked to a COVID-19 cluster; OR

    2. A suspect case with chest imaging showing findings suggestive of COVID-19 disease; OR

    3. A person with recent onset of anosmia (loss of smell) or ageusia (loss of taste) in the absence of any other identified cause

    Children/Young Adults with Confirmed SARS-Cov-2 Infection

    1. A person with a positive Nucleic Acid Amplification Test (NAAT); OR

    2. A person with a positive SARS-CoV-2Antigen-RDT AND meeting either the probable case definition or suspect criteria A OR B; OR

    3. An asymptomatic person with a positive SARS-CoV-2 Antigen-RDT who is a contact of a probable or confirmed case

    Children/Young Adults with Asymptomatic SARS-CoV-2 Infection

    1. A person without history of acute COVID-19 symptoms who has one or more of the epidemiological exposures for suspected infection and who also meets criteria b or c for suspected or probable infection, or who meets any of the criteria for confirmed infection

    2. A person without history of acute COVID-19 symptoms who has positive nucleocapsid antibody test result in medical history or Tier 1 testing with or without NAAT or RDT testing or known contact to a probable or confirmed case.

    Non-Infected Cohort

    A person who meets the following criteria will qualify for enrollment as a non-infected control subject:

    1. Does not meet WHO criteria for a suspected, probable, or confirmed case of SARS-CoV-2 infection AND

    2. Does not have serological evidence of past asymptomatic SARS-CoV-2 infection in medical history or Tier 1 testing, AND

    3. Lives in the same communities or recruited from the same sources as those in the SARS-CoV-2 infected cohort, AND

    4. Either not hospitalized for any reason in prior 3 months, or hospitalized (with or without ICU stay) within the prior 3 months

    5. Uninfected individuals may participate independent of their vaccination status

    6. Uninfected individuals who develop SARS-CoV-2 infection during the study period will be reassigned to the SARS-Cov-2 infected group and will be considered to have been enrolled prior to SARS-CoV-2 infection.

    Children (≤3 years of age) born in and out of the context of maternal SARS-CoV-2 infection during pregnancy.

    1. Children ≤3 years of age born to a childbearing parent with history of suspected, probable, or confirmed SARS-COV-2 infection during pregnancy (according the same criteria listed for the infected child cohort) will be enrolled in the study from existing research cohorts at the maternal fetal medicine sites in the RECOVER. network.

    2. Children ≤3 years of age born to a childbearing parent without history of SARS-COV-2 infection during pregnancy (according to the same criteria listed for the non-infected child cohort) will also be enrolled from the same existing research cohorts at maternal fetal medicine sites in the RECOVER network.

    Children with MIS-C

    Children/young adults with SARS-CoV-2 infection who have history of MIS-C meeting the CDC definition:

    1. An individual aged <21 years presenting with fever*, laboratory evidence of inflammation**, and evidence of clinically severe illness requiring hospitalization, with multisystem (>2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological); AND

    2. No alternative plausible diagnoses; AND

    3. Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or exposure to a suspected or confirmed COVID-19 case within the 4 weeks prior to the onset of symptoms.

    • Fever >38.0°C for ≥24 hours, or report of subjective fever lasting ≥24 hours **Including, but not limited to, one or more of the following: an elevated C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, procalcitonin, d-dimer, ferritin, lactic acid dehydrogenase (LDH), or interleukin 6 (IL-6), elevated neutrophils, reduced lymphocytes and low albumin Young adults with past history of MIS-C with current ages 22-25 years are eligible to participate.

    Children/Young Adults with Post-Vaccine Myocarditis

    1. Age 3-25 years

    2. Recipient of mRNA COVID-19 vaccination within last 4 weeks

    3. Children or young adults with or without history of SARS-CoV-2 infection are eligible

    4. Children or young adults with or without history of MIS-C are eligible (if any prior MIS-C-related cardiac abnormalities are known to have resolved pre-vaccination)

    5. No other known auto-immune or other immune dysregulation disease

    6. Participants are eligible without exclusion related to sex, race/ethnicity, geography, nationality, severity of disease, or underlying health conditions

    7. Clinical evidence of probable or confirmed myocarditis based on the following criteria:

    Children and young adults ages 3-25 years with presence of ≥1 new or worsening of the following clinical symptoms:

    • chest pain, pressure, or discomfort

    • dyspnea, shortness of breath, or pain with breathing

    • palpitations

    • syncope

    OR, children aged 3-12 years might instead have ≥2 of the following symptoms:
    • irritability

    • vomiting

    • poor feeding

    • tachypnea

    • lethargy AND

    ≥1 new finding of:

    • troponin level above upper limit of normal (any type of troponin)

    • abnormal electrocardiogram (ECG or EKG) or rhythm monitoring findings consistent with myocarditis

    • abnormal cardiac function or wall motion abnormalities on echocardiogram

    • cardiac MRI findings consistent with myocarditis

    • histopathologic confirmation of myocarditis (Definite myocarditis)¶ AND

    • No other identifiable cause of the symptoms and finding

    Entry criteria are adapted from the CDC definition based on the assumptions that COVID-19 vaccines will be available in the future to children <5 years of age.

    Primary Caregiver Entry Criteria

    1. A primary caregiver is defined as an individual, such as a family member (biological or nonbiological) or legal guardian, who is responsible for the care of the enrolled child and resides in the same household as the child. When possible, the primary caregiver identified at study entry will remain in the same role throughout the study.

    2. The primary caregiver is the caregiver who spends the most time with the child or young adult, has substantial responsibility for taking care of him/her on a daily basis, and is most knowledgeable about him/her.

    3. If two or more persons share equally in the caregiver responsibilities for the child or young adult, the person selected by the family to fill out study forms both about themselves and the child will be considered the primary caregiver.

    4. If a biological family member primary caregiver has not reached the legal age of majority in their jurisdiction, the parent/legal guardian for the minor primary caregiver will provide consent for participation, with assent provided by the minor caregiver.

    5. A nonbiological primary caregiver or legal guardian serving as primary caregiver must be above the legal age of majority in their jurisdiction.

    6. The primary caregiver cannot be a babysitter or other childcare provider who receives money to care for the child.

    Biological Parent Entry Criteria

    • If the primary caregiver is a biological parent of the child or young adult who is participating in the study, the other biological parent may be enrolled to provide a home sample of saliva for DNA analysis.

    Exclusion Criteria

    An individual who meets any of the following criteria will be excluded from participation in this study:

    1. Any child, young adult, caregiver, or other biological parent who in the opinion of the site investigator may be at increased risk of adverse events during participation in the study, or who may not be able to complete study procedures due to co-morbid disease or disability.

    2. Any young adult age above the age of majority who lacks capacity to provide consent

    3. Nonviable neonates and neonates of uncertain viability as determined by the treating physician

    4. Any child, young, adult, or caregiver with co-morbid illness with expected survival <2 years

    5. Any child who is being given up for adoption or is a ward of the state

    6. Any caregiver or other biological parent who is incarcerated, or who lacks capacity to provide consent

    7. Currently enrolled in the study Understanding the Long-term Impact of COVID-19 in Adults

    Contacts and Locations

    Locations

    SiteCityStateCountryPostal Code
    1University of Alabama at Birmingham (Pregnancy Cohort)BirminghamAlabamaUnited States35294
    2Arkansas Children's Hospital and Research InstituteLittle RockArkansasUnited States72202
    3University of California San DiegoLa JollaCaliforniaUnited States92093
    4Children's Hospital Los AngelesLos AngelesCaliforniaUnited States90027
    5University of California San Diego Health - Rady Children's HospitalSan DiegoCaliforniaUnited States92123
    6University of California San Francisco (Pregnancy Cohort)San FranciscoCaliforniaUnited States94115
    7University of California San FranciscoSan FranciscoCaliforniaUnited States94143
    8University of California, San Francisco (UCSF)San FranciscoCaliforniaUnited States94143
    9Connecticut Children's Medical CenterHartfordConnecticutUnited States06106
    10Yale School of Medicine (YSM)New HavenConnecticutUnited States06510
    11ChristianaCare Health SystemNewarkDelawareUnited States19718
    12Nemours Children's HealthWilmingtonDelawareUnited States19803
    13Kapi'olani Medical Center for Women & ChildrenHonoluluHawaiiUnited States96826
    14Northwestern UniversityEvanstonIllinoisUnited States60208
    15Northshore University HealthSystemGlenviewIllinoisUnited States60026
    16American Academy of PediatricsItascaIllinoisUnited States60143
    17American Academy of Family PhysiciansLeawoodKansasUnited States66211
    18University of Louisville - Norton Children's HospitalLouisvilleKentuckyUnited States40202
    19Louisiana State University (LSU) - Pennington Biomedical Research CenterBaton RougeLouisianaUnited States70808
    20Ochsner Health SystemNew OrleansLouisianaUnited States70115
    21Tulane UniversityNew OrleansLouisianaUnited States70118
    22Johns Hopkins UniversityBaltimoreMarylandUnited States21218
    23Mass General Brigham - Harvard UniversityBostonMassachusettsUnited States02114
    24Harvard School of Public HealthBostonMassachusettsUnited States02115
    25Northeastern UniversityBostonMassachusettsUnited States02115
    26Central Michigan University - College of MedicineDetroitMichiganUnited States48201
    27Mayo ClinicRochesterMinnesotaUnited States55905
    28University Of Nebraska Medical CenterOmahaNebraskaUnited States68198
    29Dartmouth-HitchcockLebanonNew HampshireUnited States03766
    30Hackensack University Medical CenterHackensackNew JerseyUnited States07601
    31Rutgers UniversityNew BrunswickNew JerseyUnited States08901
    32Saint Peter's University HospitalNew BrunswickNew JerseyUnited States08901
    33The Pediatric Specialty Center at Saint BarnabasWest OrangeNew JerseyUnited States07052
    34University of New Mexico Health Sciences CenterAlbuquerqueNew MexicoUnited States87102
    35NYU Langone HealthNew YorkNew YorkUnited States10016
    36Columbia UniversityNew YorkNew YorkUnited States10027
    37NewYork-Presbyterian HospitalQueensNew YorkUnited States11355
    38New York Medical CollegeValhallaNew YorkUnited States10595
    39University of North Carolina (UNC) at Chapel HillChapel HillNorth CarolinaUnited States27516
    40Duke University Medical CenterDurhamNorth CarolinaUnited States27710
    41WakeMed Health & HospitalsRaleighNorth CarolinaUnited States27610
    42Good Samaritan HospitalCincinnatiOhioUnited States45220
    43University Hospitals MacDonald's Women's HospitalClevelandOhioUnited States44106
    44Metrohealth SystemClevelandOhioUnited States44109
    45The MetroHealth System (Pregnancy Cohort)ClevelandOhioUnited States44109
    46The Ohio State University - Wexner Medical CenterColumbusOhioUnited States43210
    47Miami Valley HospitalDaytonOhioUnited States45409
    48Children's Mercy HospitalFairfieldOhioUnited States45014
    49University of Oklahoma Health Sciences Center (OUHSC)Oklahoma CityOklahomaUnited States73104
    50Children's Hospital of PhiladelphiaPhiladelphiaPennsylvaniaUnited States19104
    51University of PennsylvaniaPhiladelphiaPennsylvaniaUnited States19104
    52University of Pittsburgh Medical Center (UPMC)PittsburghPennsylvaniaUnited States15213
    53Rhode Island HospitalProvidenceRhode IslandUnited States02903
    54Women & Infants HospitalProvidenceRhode IslandUnited States02905
    55Medical University of South Carolina (MUSC)CharlestonSouth CarolinaUnited States29425
    56Prisma Health UpstateGreenvilleSouth CarolinaUnited States29605
    57Avera Research InstituteSioux FallsSouth DakotaUnited States57108
    58St. David's Health CareAustinTexasUnited States78758
    59University of Texas Medical Branch (UTMB) GalvestonGalvestonTexasUnited States77555
    60Lyndon B. Johnson (LBJ) HospitalHoustonTexasUnited States77024
    61Memorial Hermann Health SystemHoustonTexasUnited States77024
    62Baylor College of MedicineHoustonTexasUnited States77030
    63UTMB Health League City Campus Hospital & ClinicsLeague CityTexasUnited States77573
    64McKay-Dee HospitalOgdenUtahUnited States84403
    65Utah Valley Regional Medical CenterProvoUtahUnited States84604
    66Intermountain Medical Center (Intermountain Healthcare)Salt Lake CityUtahUnited States84107
    67University of Utah HealthSalt Lake CityUtahUnited States84132
    68LDS Hospital - Intermountain HealthcareSalt Lake CityUtahUnited States84143
    69University of Vermont (UVM) Children's HospitalBurlingtonVermontUnited States05401
    70Virginia Commonwealth UniversityRichmondVirginiaUnited States23284
    71West Virginia UniversityMorgantownWest VirginiaUnited States26506
    72Medical College Of WisconsinMilwaukeeWisconsinUnited States53226

    Sponsors and Collaborators

    • NYU Langone Health
    • National Heart, Lung, and Blood Institute (NHLBI)

    Investigators

    • Principal Investigator: Stuart Katz, MD, MS, NYU Langone Health
    • Principal Investigator: Andrea Troxel, ScD, NYU Langone Health
    • Principal Investigator: Leora Horwitz, MD, NYU Langone Health

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    NYU Langone Health
    ClinicalTrials.gov Identifier:
    NCT05172011
    Other Study ID Numbers:
    • 21-01231
    First Posted:
    Dec 29, 2021
    Last Update Posted:
    Feb 7, 2022
    Last Verified:
    Feb 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by NYU Langone Health
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 7, 2022